By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
ScienceabodeScienceabode
  • Home
  • News & Perspective
    News & PerspectiveShow More
    Microorganism that causes rare but severe eye infections detected in NSW coastal areas
    By Admin
    Scientists identify common cause of gastro in young children and adults over 50 years old
    By admin
    AI reveals hidden traits about our planet’s flora to help save species
    By admin
    Eye drops slow nearsightedness progression in kids, study finds
    By admin
    Using AI to create better, more potent medicines
    By admin
  • Latest News
    Latest NewsShow More
    Researchers develop new robot medics for places doctors are unable to be
    By Admin
    Even thinking about marriage gets young people to straighten up
    By admin
    Study: People tend to locate the self in the brain or the heart – and it affects their judgments and decisions
    By admin
    UCLA patient is first to receive successful heart transplant after using experimental 50cc Total Artificial Heart
    By admin
    Via Dying Cells, UVA Finds Potential Way to Control Cholesterol Levels
    By admin
  • Health
    Health
    The World Health Organization defines health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.”…
    Show More
    Top News
    World’s largest study of brain volume reveals genetic links to ADHD, Parkinson’s Disease 
    October 26, 2024
    Chemicals produced by fires show potential to raise cancer risk
    November 11, 2024
    Rising rates of head and neck cancers in England
    October 26, 2024
    Latest News
    Game-Changer in Emergency Medicine: New AI Test Flags Sepsis Hours Before Symptoms Worsen
    June 4, 2025
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    June 3, 2025
    Medical Milestone: Surgeons Perform First-Ever Human Bladder Transplant
    May 20, 2025
    A Downside of Taurine: It Drives Leukemia Growth
    May 19, 2025
  • Environment
    EnvironmentShow More
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    By Admin
    Arsenic exposure linked to faster onset of diabetes in south Texas population 
    By Admin
    Antarctica vulnerable to invasive species hitching rides on plastic and organic debris
    By Admin
    New substrate material for flexible electronics could help combat e-waste
    By Admin
    Bacteria ‘nanowires’ could help scientists develop green electronics
    By Admin
  • Infomation
    • Pricavy Policy
    • Terms of Service
  • Jobs
  • Application Submission
Notification Show More
Aa
ScienceabodeScienceabode
Aa
  • Home
  • Health
  • Anatomy
  • Jobs Portal
  • Application Submission
  • Categories
    • Health
    • Anatomy
    • Food & Diet
    • Beauty Lab
    • News & Perspective
    • Environment
  • More Foxiz
    • Blog Index
    • Sitemap
Follow US
Scienceabode > Blog > Uncategorized > FDA approves drug which helps to slow progression of rare form of MND
Uncategorized

FDA approves drug which helps to slow progression of rare form of MND

admin
Last updated: 2023/05/13 at 7:21 PM
By admin
Share
5 Min Read
SHARE

Lumbar Puncture - treatment for MND

Credit: NIHR Sheffield Biomedical Research Center

The Food and Drug Administration (FDA) in the US has authorised the first approved drug for a rare form of motor neurone disease (MND) based on the results of a Phase 3 clinical trial completed at the University of Sheffield, the UK centre for the international trial.

- Advertisement -
MedBanner_Skyscraper_160x600_03/2018

Results from the Phase 3 clinical trial, led in the UK by Professor Dame Pamela Shaw, Director of the Neuroscience Institute and the Sheffield Institute for Translational Neuroscience (SITraN) and Professor Chris McDermott, Professor of Translational Neurology at the University of Sheffield, showed patients with the faulty SOD1 gene often noticed a slowing of the progression of their symptoms and in some cases improvement of muscle strength after taking the investigational drug QALSODY™, formerly known as Tofersen.

Biotechnology company Biogen Inc. is responsible for bringing the new drug to the US market and researchers expect applications for UK and EU approvals to be submitted in the near future.

This is a major scientific advance as the first treatment to target a genetic cause of MND and will change the way researchers conduct clinical trials in MND in the future.

The trial included 108 MND patients known to have the faulty SOD1 gene. Although a significant clinical improvement was not found at the primary endpoint of the study at 28 weeks, when the monitoring period was extended to 52 weeks, notable clinical improvements were observed in terms of muscle strength, breathing function and disability levels.

Professor Dame Pamela Shaw from the University of Sheffield, said: “I have conducted more than 25 MND clinical trials and this is the first trial in which patients have reported an improvement in their muscle strength.

“Never before have I heard patients say ‘I am doing things today that I couldn’t do a few months ago – walking up the garden steps or writing Christmas cards’. For me this is an important treatment milestone.”

She added: “This trial taught us that we can see changes in biochemistry within 2-3 months but we have to be a bit more patient to see the significant clinical changes.

“We found that we can reduce or slow damage from happening biologically, but it takes more time for the motor neurones to heal and regenerate their connections with the muscles. So, the motor system needs time to heal before we see a significant clinical change.

“Although not yet approved for use in the UK and Europe, FDA approval is a major scientific development . While awaiting the regulatory permissions to prescribe QALSODY™, Biogen are making the treatment available for patients with a confirmed SOD1 mutation through an expanded access programme.”

Results of the Phase 3 clinical trial (VALOR), published in the New England Journal of Medicine, showed that biomarkers in patients’ cerebrospinal fluid showed a reduction in the SOD1 and neurofilament protein levels after taking QALSODY for six months. This suggests that the treatment successfully hits the therapeutic target and reduces loss of motor neurones, which may allow them to start regenerating connections with muscles in the body. However, it took longer for patients to experience improved muscle strength.

Patients receive QALSODY as an injection into the cerebrospinal fluid by lumbar puncture every 4 weeks. The drug was found to be generally safe, though a small number of patients developed reversible inflammation of the spinal cord or nerve roots.

Researchers now hope that the FDA approval will help to pave the way for approvals in other countries and for new treatments tackling other genetic causes of MND to be developed. The results from this landmark trial will improve the clinical trial landscape for MND generally and allow researchers to measure whether an experimental treatment is beneficial much more quickly than has been possible up until now.

Source: University of Sheffield

Published on May 13, 2023

TAGGED: ALS, MND, motor neuron disease
admin May 13, 2023 May 13, 2023
Share This Article
Facebook Twitter Copy Link Print

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Even in Winter, Life Persists in Arctic Seas

(USCGC Healy breaking through the Bering Sea waves. Credit: Chantelle Rose/NSF)   Despite…

A Biodiversity Discovery That Was Waiting in the Wings–Wasp Wings, That Is

Wing size differences between two Nasonia wasp species are the result of…

Entertainement

Coming soon

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

New psychological therapy shows promise in improving quality of life for people living with MND

By Admin
Uncategorized

Microorganism that causes rare but severe eye infections detected in NSW coastal areas

By Admin
Uncategorized

Scientists identify common cause of gastro in young children and adults over 50 years old

By admin
Uncategorized

AI reveals hidden traits about our planet’s flora to help save species

By admin
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Editorial Policy
  • Accessibility Statement
  • Contact US
  • Feedback
  • Advertisement
More Info
  • Newsletter
  • Beauty Lab
  • News & Perspective
  • Food & Diet
  • Health
  • Environment
  • Anatomy

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

Copyright © 2023 ScienceAbode. All Rights Reserved. Designed and Developed by Spirelab Solutions (Pvt) Ltd

Welcome Back!

Sign in to your account

Lost your password?